Comprehensive assessment of the medical uses of N-Acetyl-Cysteine serves as a single resource for information on this therapeutic

In depth consideration of biological mechanisms puts therapeutic effects in context

Includes a dedicated chapter on safety and special formulations

Dr. Richard Frye is the Chief of Neurodevelopmental Disorders at the Barrow Neurological Institute at Phoenix Children’s Hospital and Professor of Child Health at the University of Arizona College of Medicine - Phoenix.

Professor Michael Berk is a NHMRC Senior Principal Research Fellow, and is Alfred Deakin Chair of Psychiatry at Deakin University and Barwon Health in Melbourne Australia.